Always Remember - Buy The Dip

If you have trouble remembering please watch the video below. Definitely some language.

Sentiment Analysis For SCYX

The news is currently generally neutral for SCYX.

Based on TextBlob analysis of Yahoo! Finance news summaries for SCYX on 2015-08-22.

Yahoo! Finance News for SCYX

Health Care Sector Update for 04/23/2015: SCYX,ADPT,ALXN
Top Health Care Stocks JNJ +0.24% PZE +1.17% MRK +0.31% ABT +0.05% AMGN +0.12% Health care stocks were higher in afternoon trade with the NYSE Health Care Sector Index advancing about 0.5% and shares of health care companies in

Fungus fighter Cidara Therapeutics sets terms for $60 million IPO
Cidara Therapeutics, which is developing novel therapies for fungal infections, announced terms for its IPO on Monday. The San Diego, CA based company plans to raise $60 million by offering 4.0 million shares at a price range of $14

Fungus beware: Cidara Therapeutics files for a $69 million IPO
Cidara Therapeutics, which is developing novel therapies for fungal infections, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Last year's antifungal biotech SCYNEXIS ( SCYX ) trades at about its

US IPO Recap: 16 IPOs in a row price below their midpoint
Including last week's 3 IPOs, 16 companies in a row have now priced below the midpoint of the original range, the longest streak in at least 15 years. The 16 IPOs in the last three weeks have

SCYNEXIS prices IPO at $10, as expected
SCYNEXIS, a biotech developing treatments for life threatening fungal infections, raised $62 million by offering 6.2 million shares at $10, as expected. SCYNEXIS plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and

SCYNEXIS increases deal size to $62 million but slashes market cap
SCYNEXIS, a biotech developing treatments for life threatening fungal infections, raised the proposed deal size for its upcoming IPO on Wednesday. The Durham, NC based company now plans to raise $62 million by offering 6.2 million shares

4 US IPOs planned for the week of Apr 28
The following IPOs are expected to price this week Aldeyra Therapeutics ( ALDX ), a clinical stage biotech developing treatments for rare skin and eye diseases, plans to raise $13 million by offering 1.2 million shares

4 US IPOs planned for the week of Apr 21
The following IPOs are expected to price this week Aldeyra Therapeutics ( ALDX ), a clinical stage biotech developing treatments for rare skin and eye diseases, plans to raise $25 million by offering 2.3 million shares

SCYNEXIS increases shares offered and drops its range to $7 to $8
SCYNEXIS, a biotech developing treatments for life threatening fungal infections, lowered the range for its upcoming IPO on Wednesday. The Durham, NC based company now plans to raise $55 million by offering 7.3 million shares at a

Fungal infections biotech SCYNEXIS sets terms for $55 million IPO
SCYNEXIS, a biotech developing treatments for life threatening fungal infections, announced terms for its IPO on Wednesday. The Durham, NC based company plans to raise $55 million by offering 4.2 million shares at a price range of